Executive Briefings

UPS to Acquire Healthcare Logistics Company Marken

UPS has entered into a definitive purchase agreement to acquire Marken, a global provider of supply chain solutions to the life sciences industry. The transaction, which provides UPS with growth opportunities across the life sciences customer base, is expected to close by Dec. 31, UPS said. Terms of the acquisition were not disclosed.

Clinical trials require strict regulatory compliance, streamlined logistics services and global reach, and Marken operates a global network of clinical supply chain services to meet the increasingly complex demands of its clients. The acquisition of Marken follows multiple UPS acquisitions that have expanded the company's healthcare logistics services portfolio.

"Healthcare logistics is a strategic market for UPS. Our acquisition of Marken strengthens our portfolio and demonstrates our commitment to customers," said Teresa Finley, UPS chief marketing and business services officer.

Marken collects and transports clinical trial material and investigational medicinal products to 49,000 clinical trial sites, and ships biological samples from these sites to central laboratories. These shipments are time- and temperature-sensitive, and their rapid, on-spec delivery is a key factor in the treatment of patients and the success of the clinical trial, Marken says. The company has more than 650 employees with an asset-light operating structure and 44 locations worldwide, including 10 depots that are compliant with Good Manufacturing Practices (GMP). Marken provides service to pharmaceutical companies, manufacturers and contract research organizations engaged in all phases of the clinical trials process.

CEO Wes Wheeler will continue to lead the Marken business, which will operate as a wholly-owned subsidiary of UPS.

Source: UPS

Clinical trials require strict regulatory compliance, streamlined logistics services and global reach, and Marken operates a global network of clinical supply chain services to meet the increasingly complex demands of its clients. The acquisition of Marken follows multiple UPS acquisitions that have expanded the company's healthcare logistics services portfolio.

"Healthcare logistics is a strategic market for UPS. Our acquisition of Marken strengthens our portfolio and demonstrates our commitment to customers," said Teresa Finley, UPS chief marketing and business services officer.

Marken collects and transports clinical trial material and investigational medicinal products to 49,000 clinical trial sites, and ships biological samples from these sites to central laboratories. These shipments are time- and temperature-sensitive, and their rapid, on-spec delivery is a key factor in the treatment of patients and the success of the clinical trial, Marken says. The company has more than 650 employees with an asset-light operating structure and 44 locations worldwide, including 10 depots that are compliant with Good Manufacturing Practices (GMP). Marken provides service to pharmaceutical companies, manufacturers and contract research organizations engaged in all phases of the clinical trials process.

CEO Wes Wheeler will continue to lead the Marken business, which will operate as a wholly-owned subsidiary of UPS.

Source: UPS